Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Operating Leases (2021 - 2025)

Historic Operating Leases for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Q3 2025 value amounting to $3.5 million.

  • Rhythm Pharmaceuticals' Operating Leases fell 1277.92% to $3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 million, marking a year-over-year decrease of 1277.92%. This contributed to the annual value of $3.9 million for FY2024, which is 70367.35% up from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Operating Leases stood at $3.5 million for Q3 2025, which was down 1277.92% from $3.7 million recorded in Q2 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Operating Leases peaked at $4.0 million during Q3 2024, and registered a low of $284000.0 during Q1 2024.
  • In the last 5 years, Rhythm Pharmaceuticals' Operating Leases had a median value of $1.6 million in 2022 and averaged $2.1 million.
  • In the last 5 years, Rhythm Pharmaceuticals' Operating Leases tumbled by 7360.59% in 2024 and then skyrocketed by 125176.06% in 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Operating Leases (Quarter) stood at $1.9 million in 2021, then tumbled by 35.22% to $1.3 million in 2022, then tumbled by 61.11% to $490000.0 in 2023, then soared by 703.67% to $3.9 million in 2024, then dropped by 10.74% to $3.5 million in 2025.
  • Its last three reported values are $3.5 million in Q3 2025, $3.7 million for Q2 2025, and $3.8 million during Q1 2025.